![](/images/graphics-bg.png)
Rho-KinaseROCK as a Potential Drug Target for Vitreoretinal Diseases
Joint Authors
Yamaguchi, Muneo
Arima, Mitsuru
Wada, Iori
Kaizu, Yoshihiro
Hao, Feng
Yoshida, Shigeo
Sonoda, Koh-hei
Nakao, Shintaro
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-05-17
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Rho-associated kinase (Rho-kinase/ROCK) was originally identified as an effector protein of the G protein Rho.
Its involvement in various diseases, particularly cancer and cardiovascular disease, has been elucidated, and ROCK inhibitors have already been applied clinically for cerebral vasospasm and glaucoma.
Vitreoretinal diseases including diabetic retinopathy, age-related macular degeneration, and proliferative vitreoretinoapthy are still a major cause of blindness.
While anti-VEGF therapy has recently been widely used for vitreoretinal disorders due to its efficacy, attention has been drawn to new unmet needs.
The importance of ROCK in pathological vitreoretinal conditions has also been elucidated and is attracting attention as a potential therapeutic target.
ROCK is involved in angiogenesis and hyperpermeability and also in the pathogenesis of various pathologies such as inflammation and fibrosis.
It has been expected that ROCK inhibitors will become new molecular target drugs for vitreoretinal diseases.
This review summarizes the recent progress on the mechanisms of action of ROCK and their applications in disease treatment.
American Psychological Association (APA)
Yamaguchi, Muneo& Nakao, Shintaro& Arima, Mitsuru& Wada, Iori& Kaizu, Yoshihiro& Hao, Feng…[et al.]. 2017. Rho-KinaseROCK as a Potential Drug Target for Vitreoretinal Diseases. Journal of Ophthalmology،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1185515
Modern Language Association (MLA)
Yamaguchi, Muneo…[et al.]. Rho-KinaseROCK as a Potential Drug Target for Vitreoretinal Diseases. Journal of Ophthalmology No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1185515
American Medical Association (AMA)
Yamaguchi, Muneo& Nakao, Shintaro& Arima, Mitsuru& Wada, Iori& Kaizu, Yoshihiro& Hao, Feng…[et al.]. Rho-KinaseROCK as a Potential Drug Target for Vitreoretinal Diseases. Journal of Ophthalmology. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1185515
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1185515